Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial
2011

Renal function during rofecoxib therapy in cancer patients

Sample size: 87 publication Evidence: moderate

Author Information

Author(s): Reinhold Stephan W, Reichle Albrecht, Leiminger Sonja, Bergler Tobias, Hoffmann Ute, Krüger Bernd, Banas Bernhard, Krämer Bernhard K

Primary Institution: University of Regensburg

Hypothesis

The study aimed to analyze the impact of rofecoxib therapy on renal function in patients with metastatic cancer.

Conclusion

Rofecoxib therapy leads to a decrease in renal function in nearly every patient treated.

Supporting Evidence

  • 86% of patients experienced a decrease in renal function during the first month of treatment.
  • Mean serum creatinine concentration increased by about 0.15 mg/dl during the first three months.
  • Estimated glomerular filtration rate decreased from 90.3 ml/min to a minimum of 76 ml/min during treatment.

Takeaway

This study found that taking rofecoxib can make your kidneys work less well, especially in cancer patients.

Methodology

87 patients with metastatic cancer were treated with rofecoxib and followed for changes in renal function over 12 months.

Potential Biases

Potential bias due to the study being retrospective and the market withdrawal of the drug.

Limitations

The study was stopped due to the withdrawal of rofecoxib from the market, limiting further investigation.

Participant Demographics

Patients had a mean age of 60.5 years, with 64% male and 36% female.

Statistical Information

P-Value

p < 0.0001

Statistical Significance

p < 0.0001

Digital Object Identifier (DOI)

10.1186/1756-0500-4-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication